Stay updated on Durvalumab & Olaparib in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Durvalumab & Olaparib in Endometrial Cancer Clinical Trial page.

Latest updates to the Durvalumab & Olaparib in Endometrial Cancer Clinical Trial page
- Check6 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. No substantive content changes to the study details or page functionality were observed.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedResults have been posted for NCT04269200, with enrollment updated to 805 and 202 locations (including Erlangen, Germany). The page now lists a broad set of outcome measures (PFS, OS, PFS2, ORR, DoR, TFST, TSST, TDT, PK, ADA, and HRQoL) along with their assessment schedules.SummaryDifference1%

- Check27 days agoChange DetectedLocations for many US states and Canadian provinces were added and removed, and a Revision: v3.3.3 appears, signaling an update to the listing of study sites.SummaryDifference1%

- Check49 days agoChange DetectedThe page now shows Revision: v3.3.2, replacing Revision: v3.3.1.SummaryDifference0.0%

- Check56 days agoChange DetectedAdded a note that PubMed-derived publications are automatically filled for the study page and may not be about the study, and updated the revision to v3.3.1; removed the previous PubMed note and Revision: v3.2.0.SummaryDifference0.0%

- Check63 days agoChange DetectedDeleted the generic government operating status notice from the page, which does not affect the study data or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Durvalumab & Olaparib in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab & Olaparib in Endometrial Cancer Clinical Trial page.